Stada and alvotech secure approval for uzpruvo, europe's first ustekinumab biosimilar to stelara

Partners stada and alvotech today announced that the european commission issued a marketing authorization for uzpruvo® (avt04), a biosimilar candidate to stelara® (ustekinumab). the centralized marketing authorization for europe's first ustekinumab biosimilar is valid in all european economic area (eea) countries, including the 27 european union (eu) member states as well as in iceland, liechtenstein, and norway.
ALVO Ratings Summary
ALVO Quant Ranking